Alaunos Therapeutics, Inc.

XNAS

Last traded price · USD

$1.80

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:57 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $1.80
Volume: 230
Day's high: —
Day's low: —

In brief

Alaunos Therapeutics, Inc. is a US-listed company listed on Nasdaq, valued at about $5M.
Its shares closed at $1.80 on 4 Nov 2026, down 28.6% over the past year.
From India you can buy TCRT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Alaunos Therapeutics, Inc. (TCRT) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole TCRT share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade TCRT options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY over 1 year
1 month: +142.4% (SPY −1.6%). 3 months: −10.9% (SPY −0.4%). 1 year: −28.6% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: TCRT, SPY · as of 4 Nov 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $1.80 was 9.7% above its 50-day average ($1.64) and 22.3% below its 200-day average ($2.32). It has closed below the 200-day for 9 sessions, since 23 Oct 2026. The 50-day average crossed below the 200-day on 18 May 2026, 118 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 24.7% of shares outstanding
818.6K shares were sold short at the 15 Oct 2026 settlement, 24.7% of the 3.3M shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
29% of the way up its 52-week range
Closed at $1.80 on 4 Nov 2026: 60.0% below the 52-week high of $4.50 (12 Dec 2025) and 150.3% above the low of $0.72 (6 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+142.4%

6 months−31.6%

1 year−28.6%

5 years—

Newswire

About

Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.

Website

Notable moves

October 13, 2026
+188.57%
January 4, 2024
+56.21%
August 15, 2023
−64.68%

Alaunos Therapeutics, Inc.

XNAS

Last traded price · USD

$1.80

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:57 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $1.80
Volume: 230
Day's high: —
Day's low: —

In brief

Alaunos Therapeutics, Inc. is a US-listed company listed on Nasdaq, valued at about $5M.
Its shares closed at $1.80 on 4 Nov 2026, down 28.6% over the past year.
From India you can buy TCRT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Alaunos Therapeutics, Inc. (TCRT) shares from India?

Do I need the price of a whole TCRT share to invest?

How much can I invest in US stocks in a year?

Can I trade TCRT options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY over 1 year
1 month: +142.4% (SPY −1.6%). 3 months: −10.9% (SPY −0.4%). 1 year: −28.6% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: TCRT, SPY · as of 4 Nov 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $1.80 was 9.7% above its 50-day average ($1.64) and 22.3% below its 200-day average ($2.32). It has closed below the 200-day for 9 sessions, since 23 Oct 2026. The 50-day average crossed below the 200-day on 18 May 2026, 118 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 24.7% of shares outstanding
818.6K shares were sold short at the 15 Oct 2026 settlement, 24.7% of the 3.3M shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
29% of the way up its 52-week range
Closed at $1.80 on 4 Nov 2026: 60.0% below the 52-week high of $4.50 (12 Dec 2025) and 150.3% above the low of $0.72 (6 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+142.4%

6 months−31.6%

1 year−28.6%

5 years—

Newswire

About

Website

Notable moves

October 13, 2026
+188.57%
January 4, 2024
+56.21%
August 15, 2023
−64.68%

Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. in brief

Behind SPY over 1 year

Above its 50-day average, below its 200-day

Short interest at 24.7% of shares outstanding

29% of the way up its 52-week range

Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. in brief

Behind SPY over 1 year

Above its 50-day average, below its 200-day

Short interest at 24.7% of shares outstanding

29% of the way up its 52-week range